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Abstract
The accurate prediction of protein druggability (propensity to bind high-affinity drug-like small molecules) would greatly
benefit the fields of chemical genomics and drug discovery. We have developed a novel approach to quantitatively assess
protein druggability by computationally screening a fragment-like compound library. In analogy to NMR-based fragment
screening, we dock ,11000 fragments against a given binding site and compute a computational hit rate based on the
fraction of molecules that exceed an empirically chosen score cutoff. We perform a large-scale evaluation of the approach
on four datasets, totaling 152 binding sites. We demonstrate that computed hit rates correlate with hit rates measured
experimentally in a previously published NMR-based screening method. Secondly, we show that the in silico fragment
screening method can be used to distinguish known druggable and non-druggable targets, including both enzymes and
protein-protein interaction sites. Finally, we explore the sensitivity of the results to different receptor conformations,
including flexible protein-protein interaction sites. Besides its original aim to assess druggability of different protein targets,
this method could be used to identifying druggable conformations of flexible binding site for lead discovery, and
suggesting strategies for growing or joining initial fragment hits to obtain more potent inhibitors.
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Introduction
Since the completion of the human genome, there has been
much interest in the ‘‘druggability’’ of new potential drug targets,
and what fraction of the proteome is druggable. In this paper we
are concerned with protein druggability in the sense defined by
Hopkins and Groom [1], i.e., the ability of a protein to bind small,
drug-like molecules with high affinity. For many classes of protein
binding sites, such as the ATP binding sites in kinases, there is little
ambiguity about whether the site is druggable; the challenge in
developing inhibitors in such cases is achieving selectivity and
other desired properties. However, not all biological targets are
druggable since only certain binding sites are complementary to
drug-like compounds in terms of physicochemical properties (i.e.
size, shape, polar interactions and hydrophobicity) [1,2]. An
accurate method for predicting druggability would be particularly
valuable for assessing emerging classes of binding sites such as
protein-protein interactions (PPI) [3] and allosteric sites [4], which
are generally considered more challenging but are attracting
increasing interest in both academia and industry as drug targets.
For example, while some PPI sites have led to potent small
molecule inhibitors, others have not despite substantial effort [5,6].
A first step in evaluating target druggability is to detect the
presence of binding pockets of suitable size, shape, and
composition to accommodate drug-like molecules. Many such
methods have been developed and tested using training sets of
ligand binding sites extracted from the Protein Data Bank (PDB).
Several in-depth reviews are available that summarize computa-
tional methods for protein binding pocket detection [7,8,9], many
of which can be classified as geometry-based [10,11,12,13],
information-based [14,15] and energy-based algorithms [16,17].
Combinations of these strategies have also been developed
[18,19,20,21,22]. In addition, more complex free-energy calcula-
tion methods have also been used to predict binding sites and
identify energetically favorable binding site residues, including
computational solvent mapping [23] and grand canonical Monte
Carlo simulations [24].
The presence of a ‘‘suitable’’ protein pocket is necessary but not
sufficient to guarantee potent binding of drug-like small molecules.
A few studies have attempted to more directly predict druggability
of binding sites. Several studies have predicted protein druggability
on the basis of sequence and structural homology to known drug
targets [1,2,8]. However, not all members of the same protein
family are equally druggable [25]. More importantly, such
methods cannot be used to assess druggability of novel target
families. Recently, an alternative approach was described to
predict the maximal affinity for a passively absorbed oral drug to a
given binding site, by quantitatively approximating the physical
forces driving protein-ligand binding. Specifically, hydrophobic
surface area and curvature of the binding pocket were used to fit
the binding affinities of a training set of protein-ligand binding
complexes. Notably, this model was successfully applied to predict
the relative druggability of two novel targets before experimental
validation [26].
To date, the most extensive experimental assessment of
druggability on various targets has been performed by Hajduk
and coworkers [27]. The heteronuclear-NMR-based technique
was applied to screen fragment-like libraries against a set of 23
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revealed that small ligands bind almost exclusively to well-defined
binding pockets on the protein surface, independent of their
affinity. Remarkably, the authors observed a strong correlation
between the experimental NMR hit rate and the ability to bind
drug-like ligands with high affinity in a particular binding site.
Furthermore, they derived a linear regression model to fit the
experimentally measured hit rates to physicochemical descriptors
of these 28 binding pockets. These results suggested that the
druggability of a particular binding site is related to its propensity
to bind low-affinity, fragment-size compounds.
We wondered whether in silico fragment screening would also
be useful in this regard, with the obvious advantages of speed
and cost relative to experimental screening. Here we describe
the development and evaluation of such a method, making use
of a molecular mechanics-based scoring method for the protein-
ligand interactions (Method Section) [28,29]. Specifically, we
report the results of virtually screening ,11,000 diverse
fragment-like compounds against a total of 152 protein binding
sites, including the training dataset and external dataset studied
by Hajduk and coworkers [27]. We demonstrate that the hit rate
calculated from computationally screening a diverse fragment
library correlates with the hit rate measured experimentally
from the NMR-based screening method, despite the fact that we
could not directly replicate the experiment in silico because the
fragment libraries used for the NMR screening are proprietary.
Secondly, we show that the in silico fragment screening method
can be used to distinguish known druggable and non-druggable
targets, including both enzymes and protein-protein interaction
sites. Finally, we explore the sensitivity of the results to different
receptor conformations, including flexible protein-protein inter-
action sites.
Results and Discussion
Comparison between NMR-based and Virtual Fragment
Screening
The key results of virtual fragment screening against the
Hajduk et al. training dataset [27] are summarized in Table 1
and Figure S1. Table 1 summarizes the druggability scores
measured from NMR-based screening, predicted by an empir-
ically fitted model by Hajduk et al., and predicted by our virtual
fragment screening method. Our calculated druggability scores
correlate reasonably well with the NMR-based fragment
Table 1. Targets, binding sites, and hit rate data from NMR-based fragment screening and two different computational models.
Target Binding site PDB ID
NMR-based Screening
a
Log (Hit Rate) Model of Hajduk et al.
a
Virtual Fragment Screening
Log (Hit Rate)
AK Adenosine 1lii 20.66 20.42 0.82
Akt-PH IP3 1h10 21.91 21.98 20.51
Bcl-XL Bak 1bxl (1ysn)
c,d 20.11 20.64 0.86 (0.88)
Bir3
b Peptide 1g3f 21.03 20.72 20.62
CMPK CMP 1q3t
c 21.13 20.72 0.12
E2-31
b DNA 1dhm
c 20.71 20.72 21.05
ErmAM SAH 1qam 21.01 20.87 1.04
FBP DNA 1j4w 21.61 21.04 20.28
FKBP FK506 1fkj 20.03 20.24 0.66
FKBP 2nd site 1fkj 21.24 21.22 20.22
HI-0065 ADP 1fl9 20.82 21.28 0.59
LCK
b pTyr 1lkl 20.21 21.07 20.67
LFA IDAS 1rd4 20.40 20.35 0.74
MDM2 P53 1rv1 (1ycr)
d 20.49 20.35 0.92 (0.45)
MurI Glu 1zuw 21.93 22.00 20.12
PAK4 ATP 2cdz
c 20.78 20.63 0.85
PDZ-PSD95 Peptide 1iu0 22.00 21.99 20.60
Pin1 Peptide 1i8h 20.94 21.49 20.05
PTP1B Catalytic pTyr 1ph0 20.68 21.15 0.72
PTP1B Noncatalytic pTyr 1ph0 21.77 21.66 20.31
SARS N-term RNA 1ssk
c 21.93 21.92 20.03
SCD Substrate 1g4k 20.09 20.55 0.51
Survivin Bir3 1e31 21.97 21.99 20.37
UK Peptide 1fv9 20.40 20.81 1.46
For the NMR-based screening results and the predictive model of Hajduk et al., druggable is defined as log (Hit Rate) .21.0 and non-druggable as log (Hit Rate) #21.0;
the corresponding cut-off in our virtual fragment screening model is 0.36.
afrom Reference [27].
bThree outliners (Bir3, E2–31 DNA site and LCK pTyr binding site) identified in our study.
cStructures were not reported in the Hajduk et al. dataset.
dFor Bcl-xl and MDM2, we used two structures, peptide-bound (1bxl and 1ycr, respectively) and small ligand bound (1ysn and 1rv1, respectively).
doi:10.1371/journal.pone.0010109.t001
Druggability Prediction
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10109screening results (Figure 1) except for three binding sites (Bir3,
E2–31 DNA site, and LCK pTyr binding site), for which we
compute much lower hit rates. Our primary goal is not to
reproduce the NMR screening data per se, but to predict
druggability, as we discuss in the next section. Nonetheless, these
outliers deserve brief comment. First, the experimentally
measured binding affinity of the best fragment hits ranges are
rather weak, from 200 to 1,000 mM, for these three outliers,
several-fold higher than other targets with similar NMR hit rates
(less than 50 mM) [27]. Further, although these sites were
classified as druggable or moderately druggable based on the
NMR hit rates, no high-affinity druglike binders have been
reported to our knowledge. The LCK pTyr binding site and Bir3
have been suggested to be not druggable due to their highly polar
or very small binding sites [30]. The reported LCK pTyr site
‘‘druglike’’ ligand contains a diphosphonophenylalanine group to
target the pTyr site, and a cyclohexane ring inserts deeply into an
extra spatially distinct hydrophobic binding pocket (pTyr+3) [31],
which further indicates that LCK pTyr site is not a truly
druggable site by itself. We cannot rule out the possibility that
these outliers reflect a deficiency in our method, but for the
reasons discussed above, we have excluded them from further
analysis.
Figure 1 presents the correlation between the NMR-based
druggability score and our calculated druggability score for the
remaining 21 binding sites. Encouragingly, a reasonable correla-
tion is achieved (R
2=0.69), especially considering that the
compounds screened by NMR and by docking are different.
The empirical model developed by Hajduk et al. by fitting to this
data, using multiple adjustable parameters, gives a correlation of
R
2=0.79 for these 21 binding sites, and the slopes of the two
models are similar in Figure 1 (0.72 and 0.81, respectively).
Hajduk et al. defined binding sites as ‘‘highly druggable’’ if
they have a log(hit rate).21.0. Based on the correlation in
Figure 1, the corresponding value of the computational log(hit
rate) is 0.36, and we use this value to classify proteins as
druggable or non-druggable in the following sections. Note that,
although Hajduk et al. distinguish between ‘‘highly druggable’’
and ‘‘moderately druggable’’, we use a simple binary classifica-
tion for simplicity.
Classification of Binding Sites as Druggable/Non-
Druggable
Using the druggability score cutoffs derived above, we evaluated
the ability of the virtual fragment screening protocol to classify the
binding sites in the Hajduk et al. external dataset, which contains
72 targets, including 35 classified as druggable and 37 as non-
druggable. Table S1 summarizes the druggability scores calculated
using the empirical model of Hajduk et al. and our virtual
fragment screening method.
In evaluating the success of our method, we put more
emphasis on ‘‘true positives’’, i.e., the ability to identify
proteins as druggable when they have in fact been shown to
bind small drug-like molecules with high affinity. By contrast,
the lack of a published, potent small molecule inhibitor does
not necessarily prove that a target is not druggable, and thus
we put less emphasis on putative ‘‘false positives’’. In addition,
in practical application, incorrectly predicting a site to be non-
druggable when it is in fact druggable arguably would be worse
than incorrectly predicting a non-druggable site to be
druggable. However, it is clear from the ROC plot that a
different hit rate cutoff could also be used to reduce the
number of false positives while maintaining a relatively high
true positive rate, if desired.
As shown in Figure 2, our method is able to effectively distinguish
between druggable and non-druggable sites. Encouragingly, our
method, using the default hit rate cutoff, correctly identified almost
all the true positives except for only one case, protein kinase C
(PKC-delta). Because PKC–ligand binding was shown to be
dependent on phospholipid binding [32], it is perhaps not surprising
that our method failed to predict PKC-delta as a druggable site since
we do not treat the effects of membrane binding. With respect to
false positives, we classified several proteins that bind sugars or sugar
analogs as moderately druggable, whereas these are annotated as
non-druggable targets due to the lack of reported high-affinity
druglike binders in the literature.
Based on a survey of recent literature, a few of the putative
‘‘false positives’’ are possibly incorrectly classified as non-
Figure 1. Correlation between the experimental NMR hit rate
and our calculated druggability score (red line) for 21 binding
sites as described in the text, comparing to the Hajduk et al.
predictive model for these 21 sites (blue line). Note that three
outliers in our druggability calculation were excluded in regression
analysis, and are only labelled here for visualization purpose.
doi:10.1371/journal.pone.0010109.g001
Figure 2. ROC curve plotting the false positive rate vs the true
positive rate as a function of the score used for differentiating
druggable vs non-druggable binding sites in the external
dataset of Hajduk et al. The values for the default cutoff scores are
marked with a solid circle and shown in parentheses. For this analysis,
true positives were defined as the 35 binding sites with known high
affinity ligands, while true negatives were the remaining 37 binding sites.
doi:10.1371/journal.pone.0010109.g002
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(FABP) was annotated as a non-druggable target; however, both
ours and the empirical model of Hajduk et al. predicted it to be
highly druggable. Small fragment-like ligands were identified by
an NMR-based screening method [33], and also a high-affinity
drug-like inhibitor was recently reported to be an effective
therapeutic agent to prevent and treat metabolic diseases [34].
In contrast to prediction of Hajduk et al., our method ranked three
targets (guanylate kinase, guanine nucleotide-binding protein, and
deoxynucleoside-monophosphate-kinase) as highly druggable hits,
whereas they were annotated as non-druggable targets. Consid-
ering the similarity of these targets to well-known kinase targets,
we wonder whether these three nucleoside/nucleotide binding
proteins may prove to be druggable.
Application to Known Drug Targets with Multiple
Conformations
As an additional data set, we assembled a diverse set of well-
known drug targets that have multiple crystal complex
structures available, and generally display significant sidechain
movement upon binding to different ligands [35] (Table 2).
Thus, these targets serve as additional positive controls, and also
allow us to investigate the consequences of protein conforma-
tional flexibility.
All of these targets are predicted to be druggable based on
t h ec u t o f fo f0 . 3 6u s e da b o v e .M o s to ft h et a r g e t sh a v em u c h
higher druggability scores (.1.0), regardless of which crystal
structure was used. The lowest druggability scores of 0.45 and
0.52 were calculated for angiotensin-converting enzyme (ACE,
1o86) and neuraminidase (NA, 1a4g), respectively. These
binding sites are highly charged. It has been argued elsewhere
that such binding sites are in fact less druggable than more
hydrophobic binding sites [26]. Nevertheless, it is encouraging
that our fragment virtual screening method is capable of
assigning a reasonable druggability score to highly charged but
druggable binding sites.
The histograms of energy scores (Figure S2) and the
druggability scores calculated from them do change using
different crystal structures, as expected, but in most cases the
changes are remarkably small. The largest variation in the
virtual fragment screening results between different crystal
structures is seen for P38 MAPK, which also displays some of
the largest conformational changes: the largest movement of a
binding site side chain (RMSDmax.)i sm o r et h a n1 0A ˚,a n d
t h ea v e r a g em o v e m e n to fb i n d i n gs i t es i d ec h a i n s( R M S D ave.)
is ,4A ˚ . In the other cases, where conformational changes in
the binding site are relatively small (RMSDmax.,3A ˚ ), the
druggability scores vary only slightly, including for the cases
where ligand-free structures were available (Alr2, CDK2,
DHFR and thrombin). As shown below, the results on PPI sites
show a much more striking dependence on conformational
states.
Table 2. Druggability score calculated on 15 well-known drug targets.
Drug Target PDB ID RMSDave (A ˚) RMSDmax (A ˚) Log (Hit Rate) Drug Target PDB ID RMSDave (A ˚) RMSDmax (A ˚) Log (Hit Rate)
ACE 1uze 0.60 HIVRT 1vrt 1.66
1o86 0.17 0.37 0.45 1rt1 1.51 2.45 1.75
1uzf 0.35 0.79 0.69 1c1c
a 1.88 3.12 1.61
Alr2 1ah0 1.42 1rth
a 1.62 2.28 1.61
1ah3
a 1.06 3.19 1.27 HMGR 1hw8 1.39
2acr
a,b 0.88 1.72 1.10 1hwk 0.61 1.49 1.31
CDK2 1aq1
a 1.32 NA 1a4g 0.57
1buh
a,b 1.77 3.20 1.44 1a4q
a 0.48 2.11 0.52
1dm2
a 1.75 4.49 1.62 1nsc
a 0.34 1.49 0.52
COX-2 1cvu 1.51 P38 MAPK 1a9u 1.00
1cx2
a 1.24 3.78 1.53 1kv1 3.84 10.41 1.16
3pgh
a 1.11 3.96 1.64 1kv2 3.54 11.26 1.61
DHFR 3dfr 1.01 PDE5 1xoz 1.18
6dfr
b 1.47 1.96 1.02 1xp0 0.79 2.23 1.24
ER 1l2i 1.69 PPARg 1fm6 1.46
3ert
a 2.61 4.47 1.55 1fm9
a 1.47 4.64 1.62
1err
a 2.01 4.39 1.61 2prg
a 0.71 1.27 1.43
Fxa 1f0r 1.64 Thrombin 1ba8 1.53
1fjs 1.09 2.57 1.59 1hgt
b 0.69 1.85 1.55
1ksn
a 0.67 1.65 1.59 TK 1kim
a 1.58
1xka
a 1.27 2.46 1.56 1ki4
a 1.78 2.90 1.40
RMSDave was defined as the sidechain RMSD based on binding site residues within a cutoff distance of 4.5 A ˚ from crystallographic ligands; RMSDmax is defined as the
largest sidechain RMSD value among all the binding site residues.
aStructures used in the induced fit docking dataset of Sherman et al. [35].
bApo structure, the rest are all holo structures.
ACE, angiotensin-converting enzyme; ALR2, aldose reductase; CDK2, cyclin-dependent kinase 2; COX-2, cyclooxygenase-2; DHFR, dihydrofolate reductase; ER, estrogen
receptor; FXa, factor Xa; HIVRT, HIV reverse transcriptase; HMGR, hydroxymethylglutaryl-CoA reductase; NA, neuraminidase; P38 MAPK, P38 mitogen activated protein
kinase; PDE5, phosphodiesterase 5; PPARg, peroxisome proliferator activated receptor gamma; TK, thymidine kinase.
doi:10.1371/journal.pone.0010109.t002
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Sites
Protein-protein interactions are central to many biological
processes, and therefore represent an important class of molecular
targets for developing therapeutic agents. However, PPIs have
been historically considered to be difficult targets for small
molecular inhibitors due to the lack of suitable binding pockets
to accommodate drug-like molecules. In addition, the binding
interfaces in PPIs are generally highly conformationally flexible.
Nevertheless, important progress has been made in discovering
small molecular inhibitors of several important protein-protein
interaction targets, such as MDM2-p53, BCL-XL-BAK and
IL2-ILR [3,36]. Therefore, it is desirable to computationally
evaluate the druggability of PPIs, and identify specific druggable
conformations.
Among the PPI sites studied here, high-affinity small molecule
ligands have been found for IL-2, MDM2, BCL-XL, and HPV E2.
MDM2 and BCL-XL were correctly predicted to be druggable
regardless of which crystal structure was used. By contrast, IL-2
and HPV E2 were correctly predicted to be druggable only when
using the co-crystal structure with a small molecule inhibitor, and
not when using a crystal structure with a peptide or protein bound.
To date, only micromolar binders have been discovered for TNF
and ZipA. ZipA was predicted to be non-druggable using both
structures, while TNF was predicted to be druggable.
In general, the structural variation among different structures of
PPI targets (Table 3) is larger than in receptors or enzymes
(Table 2). For example, as illustrated in Figure 3, a remarkable
conformation change occurs upon ligand binding in IL-2. Clearly,
the druggability score varies for different protein conformations
[37], especially for IL-2, MDM2, and HPV E2 (Table 3 and
Figure S3).
Two Case Studies
Here we examine in more depth two case studies, focusing on
the chemical composition and binding modes of top-ranked
fragments. The first case study is protein tyrosine phosphatase 1B
(PTP1B). The PTP1B catalytic site and vicinal non-catalytic site
are surface-exposed, highly hydrophilic, and recognize charged
phosphotyrosine (pTyr) residue or pTyr mimetics (Figure 4A).
Characterizing the binding properties of such sites is particularly
challenging because the binding sites contain numerous polar and
charged groups, and ligand binding is a complex tradeoff between
forming favorable electrostatic interactions and the cost of
desolvation. NMR-based screening results suggested that the
catalytic site is highly druggable while the non-catalytic site is non-
druggable. The Hajduk et al. empirical model assigned the PTP1B
catalytic site as moderately druggable [27], while the computa-
tional solvent mapping technique predicted this site to be non-
druggable [23]. Encouragingly, our virtual screening method
correctly classifies the catalytic and non-catalytic sites as druggable
and non-druggable, respectively. It even reproduces the relative hit
rate observed in the NMR experiment (,10 times higher for the
catalytic site), although this may be a fortuitous result. Appropri-
ately, the high-ranking fragment hits identified for the PTP1B
catalytic site are dominated by heterocyclic carboxylic acids, and
hits for the non-catalytic site contain many neutral methyl
salicylate moieties (Figure 4B), which is consistent with previously
identified fragments from experimental screening studies (chemical
structures are shown in Figure S4) [38,39].
The second case study is P38 MAPK, which was chosen due to
its significant structural flexibility, where a new allosteric binding
site spatially distinct from the ATP catalytic pocket is induced
upon binding to a diaryl urea type of inhibitor. We focus on the
crystal structure (1kv2) bound with most potent MAPK inhibitor,
BIRB796 (Figure 5A), and the crystal structure (1kv1) bound with
a micomolar diaryl urea type of inhibitor (Figure 5B). BIRB796
binds potently by forming strong interactions to both the ATP
binding pocket and the allosteric site, including the crucial
hydrogen bonding interaction between the morpholino group
and the main chain amide of residue Met109; the hydrophobic
interaction between its naphthyl moiety and the lipophilic pocket
formed by the side chains of Lys53, Leu75, Ile84, Leu104 and
Thr106; the hydrogen bonds between the urea group and the side
chain carboxylate group of residue Glu71 and the main chain
amide of residue Asp168; and the hydrophobic interactions
between its tolyl and t-butyl groups on the pyrazole ring and the
allosteric pocket [40]. The top scoring fragment hits occupy
different binding regions. For example, pyridinyl-imidazole
scaffolds are predicted to target the ATP binding pocket, while
urea-like moieties on substituted naphthyl rings establishing
interactions with the Glu71 sidechain and the lipophilic pocket,
and substituted heterocyclic rings bury deeply into the allosteric
binding pocket (Figure 5C). It is notable that the predicted
fragment bound to the ATP binding pocket structurally resembles
an aminopyridine type of fragment identified by fragment-based
crystallography screening (chemical structures are shown in Figure
S5) [39]. The results using the crystal structure bound with a
micomolar diaryl urea type of inhibitor are similar, and high-
ranking fragment hits mimic binding interactions seen for the
picomolar inhibitor (Figure 5D).
In summary, we have developed an in silico fragment screening
method, analogous to an NMR-based screening method that was
previously shown to be effective at assessing the druggability of the
binding sites. This approach does not require fitting any
Table 3. Druggability scores calculated for 6 targets involved in protein-protein interactions.
PPI Target PDB ID RMSDave. (A ˚ ) RMSDmax. (A ˚ ) Log (Hit Rate) PPI Target PDB ID RMSDave. (A ˚ ) RMSDmax. (A ˚ ) Log (Hit Rate)
IL-2 1z92
a 0.13 MDM2 1ycr
a 0.45
1py2 2.59 5.80 0.62 1rv1 1.82 3.32 0.92
1m48 2.51 4.57 0.62 1t4e 1.57 2.91 0.66
BCL-XL 2bzw
a 1.04 HPV E2 1tue
a 20.24
2yxj 2.54 6.16 0.84 1r6n 2.80 4.32 1.02
TNF 1tnf
a 0.95 ZipA 1f47
a 20.02
2az5 2.90 5.65 0.96 1y2f 0.59 1.26 20.10
aReference structure bound with protein or peptide substrate; the remaining structures contain small molecule ligands.
doi:10.1371/journal.pone.0010109.t003
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We performed a large scale assessment on a total of 152 protein
binding sites. We demonstrated that the hit rate calculated for 21
binding sites using our approach correlates with the hit rate
measured experimentally from NMR-based screening method,
and that the method could successfully distinguish known
druggable and non-druggable targets. We are investigating
extensions of the method to identifying druggable conformations
of flexible binding sites for molecular docking, and suggesting
strategies for growing or joining initial fragment hits to obtain
more potent inhibitors.
Methods
Dataset Selection
24 binding sites (Table 1) were chosen from the training dataset
of Hajduk et al. [27] to develop our physics-based druggability
prediction model. A total of 28 binding sites were experimentally
investigated via the NMR-based fragment screening approach.
However, structural information for CMPKother, E2–31other and
Survivinother sites are not publicly available, and the crystal
structure of MurA is fosfomycin-covalent modified, so these 4
binding sites were excluded in our study. The external dataset
defined by Hajduk et al. [27] contains 72 proteins, of which 35
binding sites were assigned as druggable and the remaining 37 sites
as non-druggable, based on whether high-affinity druglike binders
could be found in the literature. We have used all 72 binding sites
(Table S1) to assess our prediction on new targets. For both the
training and the external datasets, the same protein structures
were used as in the Hajduk et al. study unless it was not reported
(i.e. Bcl-XL, CMPK, E2–31, PAK4 and SARS-RNA site).
To supplement these targets, we selected 15 well-known drug
targets from the DUD dataset [41] as true positives, and two or
more crystal structures were chosen for each target (Table 2).
Many of these structures were also used by Sherman et al. for
testing a strategy for docking against flexible binding sites [35]. We
use these flexible binding sites to evaluate the consequence of
structural flexibility in our druggability calculation. Finally, six
protein-protein interaction (PPI) targets [3] (Table 3) were chosen
from the recent literature.
To quantitate the flexibility of ligand binding sites, the crystal
structures for each target were superimposed using Chimera [42],
and root mean squared distance (RMSD) values were calculated
for each binding site residue or a combination of several binding
site residues. Residues that could not be aligned, as well as those
with missing atoms, were ignored during RMSD calculations.
Figure 4. Top ranked fragments from the virtual screen mimic portions of a known potent PTP1B inhibitor. (A) A co-crystallized ligand
(stick) is shown bound to PTP1B (1ph0), and extends across both the catalytic and non-catalytic sites. The key hydrogen bonding interactions
between the ligands and the binding site residues are illustrated with yellow lines. Different portions of the ligand are colored for comparison with
the fragments in (B). (B) Two high-ranking fragments from virtual screening. One predicted heterocyclic carboxylic acid (carbon atoms colored green,
rank 49) is shown bound to the PTP1B catalytic site, and one neutral methyl salicylate hit (carbon atoms colored magenta, rank 59) is shown bound to
the non-catalytic site. Molecular images were generated with UCSF Chimera [42].
doi:10.1371/journal.pone.0010109.g004
Figure 3. Conformational changes in IL-2. (A) IL-2 holo conformation bound with the co-crystallized ligand FRH (1py2). (B) The same ligand is
superimposed on the apo conformation of the protein (1z92), highlighting the conformational changes. Molecular images were generated with UCSF
Chimera [42].
doi:10.1371/journal.pone.0010109.g003
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The diverse set of fragments was selected from the fragment-like
subset of the ZINC database (version 6, December 2005) [43].
This subset contains 49,134 compounds with relatively low
molecular weight (MW # 250), few rotatable bonds (RB , 3),
low hydrophobicity (22 , log P , 3), and weak hydrogen
bonding potentials (HBdonor ,3 and HBacceptor ,6). We also
eliminated fragments with more than 15 heavy atoms, based on
the previous observation that maximal binding free energy
increases more slowly for ligands containing more than 15 heavy
atoms [44]. This filter reduced the library size to 32,717 molecules.
Finally, we performed structural similarity analysis to reduce
redundancy. Feature key fingerprints were calculated using
CACTVS [45] and the fingerprint-based similarity analysis was
performed with a modified version of the program SUBSET [46].
Representative structures were selected for each structural cluster
with Tanimoto coefficient (Tc) less than 0.9 to other clusters. This
further reduced the library to 11,129 diverse molecules. To assess
any potential bias resulting from the diversity-based filtering,
32,717 ZINC fragment-like compounds were used to redo the
screening for the Hajduk et al. training dataset. The computed
energy distributions are very similar (data not shown).
Computational Druggability Assessment Protocol
The detailed virtual screening protocol was published elsewhere
[28,47]; here, a brief overview is presented (Figure 6). Our scoring
method consists of two steps: predicting the binding poses of
ligands using a docking program, and then refining and rescoring
those protein-ligand complexes using a more computationally
intensive molecular-mechanics based energy function. This
protocol uses a high-throughput docking program to initially
orient and score the ZINC fragment-like compounds in the
binding site, and subjects the best single docking pose for each
docked compound to a rescoring stage in which the ligand is
energy minimized and the binding affinity is estimated using an
all-atom molecular mechanics force field combined with an
implicit solvent model. Most of the labor-intensive, manual steps
during the docking and rescoring stages were automated for large
scale application here.
The program DOCK 3.5.54 was used to dock the fragment
database into the protein binding site [48,49]. A maximum of 120
matching spheres were used to ensure adequate ligand sampling
within large binding surfaces like protein-protein interfaces.
Ligand conformations were scored based on the docking total
energy (Etot=E ele + Evdw 2 DGlig-solv), which was the sum of
electrostatic (Eele) and van der Waals (Evdw) interaction energies
corrected by the ligand partial desolvation energy (DGlig-solv) [49].
Final energies were computed after rigid-body minimization.
Then, a single docking pose with the best total energy score was
saved for each docked molecule for the next stage of scoring.
The docked protein-ligand complex and ligand were then
submitted to multi-scale Truncated Newton energy minimization
Figure 5. Top ranked fragments from the virtual screen mimic portions of known inhibitors of p38 MAP kinase. (A) The high affinity
inhibitor BIRB796 (stick) is shown bound to p38 MAP kinase (1kv2). Key hydrogen bonding interactions—between the morpholino group and the
main chain amide of residue Met109, the urea group and the side chain carboxylate group of conserved residue Glu71, and the main chain amide of
residue Asp168—are illustrated with yellow lines. Portions of the ligand are colored for comparison with fragments in panels (C) and (D). (B) A low-
affinity ligand BMU (stick) is shown bound to the allosteric pocket (1kv1). (C) Three partially overlapping top fragment hits (stick) identified from
virtual screening against the 1kv2 structure are shown: a pyridinyl-imidazole type of fragment (carbon atoms colored green, rank 155 in the virtual
screen) bound to the ATP binding pocket; a urea-like moiety on a substituted naphthyl ring (carbon atoms colored cyan, rank 55) interacting with the
Glu71 sidechain and the lipophilic pocket; and a substituted heterocyclic ring (carbon atoms colored magenta, rank 165) deeply buried into the
allosteric binding pocket. (D) The overlap of three top scored fragment hits identified from virtual screening against the 1kv1 structure (ranks 6, 136
and 210). Molecular images were generated with UCSF Chimera [42].
doi:10.1371/journal.pone.0010109.g005
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using the Protein Local Optimization Program (PLOP) [50,51,52].
The molecular mechanics forces are divided into short-range
(bond, angle, torsion, and local non-bonded) and long-range
components, with the long-range forces updated only intermit-
tently. The algorithm was also optimized for minimizations with
GB solvent that increases the computational expense by only a
factor of ,3 relative to the vacuum. Thus, this scoring approach
accounts for accurate and efficient calculations of ligand-protein
interaction energies, the ligand/receptor desolvation, and to a
lesser extent, ligand strain energies. In this work, the protein was
kept rigid during ligand-protein complex minimization to reduce
the computational expense. The binding energy (Ebind=E
R*L 2
E
L 2 E
R) was calculated by subtracting the energies of the
optimized free ligand in solution (E
L) and the free protein in
solution (E
R) from the optimized ligand-protein complex’s energy
in solution (E
R*L). The van der Waals energy component was
empirically scaled by a factor of 2 as we suggested previously [28].
To compute a ‘‘hit rate’’ for the in silico screening, we chose an
energy cutoff value empirically to maximally differentiate
druggable and non-druggable binding sites. The ‘‘druggability
score’’ in this work is defined as log(hit rate). At the present time,
docking scoring functions cannot robustly reproduce absolute
binding affinities in realistic applications. Although useful for rank-
ordering compounds [47], the molecular-mechanics based scoring
function used here also cannot be interpreted in terms of absolute
binding affinities, in part because entropy losses are not computed.
The cutoff chosen (240 kcal/mol) was based primarily on visual
inspection of the energy distributions for the 13 druggable binding
sites and 11 non-druggable sites in the Hajduk et al. training data
set. The effect of varying the cutoff is explored with respect to
differentiating between druggable and non-druggable binding sites
(Figure S6). Interestingly, the correlation between the docking
screening hit rates and the NMR screening results is relatively
insensitive to the value of the energy cutoff within a certain range
(from 240 to 234 kcal/mol). Unless stated otherwise, the results
below use an energy cutoff of 240 kcal/mol for computing the in
silico ‘‘hit rate’’.
Supporting Information
Table S1 Targets, binding sites, available ligand binding
information, and hit rate data predicted by two different
computational models.
Found at: doi:10.1371/journal.pone.0010109.s001 (0.19 MB
DOC)
Figure S1 Energy histograms from docking 11,129 ZINC
fragment-like compounds against 24 binding sites previously
studied by NMR-based fragment screening. Color code is defined
using the NMR druggability score: druggable (green): log (Hit
Rate) .21.0, and non-druggable (red): log (Hit Rate) #21.0.
Found at: doi:10.1371/journal.pone.0010109.s002 (1.56 MB TIF)
Figure S2 Histograms of energy scores from the virtual fragment
screening method for 15 well-known drug targets. ACE,
angiotensin-converting enzyme; ALR2, aldose reductase; CDK2,
cyclin-dependent kinase 2; COX-2, cyclooxygenase-2; DHFR,
dihydrofolate reductase; ER, estrogen receptor; FXa, factor Xa;
HIVRT, HIV reverse transcriptase; HMGR, hydroxymethylglu-
taryl-CoA reductase; NA, neuraminidase; P38 MAPK, P38
mitogen activated protein kinase; PDE5, phosphodiesterase 5;
PPARg, peroxisome proliferator activated receptor gamma; TK,
thymidine kinase.
Found at: doi:10.1371/journal.pone.0010109.s003 (1.59 MB TIF)
Figure S3 Energy histograms of docking 11,129 ZINC frag-
ment-like compounds against 6 targets involved in protein-protein
interactions. Color code is defined as druggable (green) and non-
druggable (red).
Figure 6. A virtual fragment screening protocol for druggability assessment.
doi:10.1371/journal.pone.0010109.g006
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Figure S4 Chemical structures of a ligand co-crystallized with
PTP1B (1ph0), binders identified in experimental screening, and
high-ranking fragment hits identified from virtual fragment
screening (fragments bound to the catalytic site are colored in
green and to the non-catalytic site in magenta).
Found at: doi:10.1371/journal.pone.0010109.s005 (1.01 MB TIF)
Figure S5 Chemical structures of a ligand co-crystallized with
P38 MAPK (1kv2), binders identified in experimental screening,
and high-ranking fragment hits identified from virtual fragment
screening using two different crystal structures, 1kv2 and 1kv1
(fragments bound to ATP site colored in green, lipophilic pocket
colored in cyan, and allosteric site in magenta).
Found at: doi:10.1371/journal.pone.0010109.s006 (1.06 MB TIF)
Figure S6 The correlation between the virtual fragment
screening hit rates and the NMR screening results, using different
energy cut-offs for defining the fragment-like compounds as ‘‘hits’’
in the virtual screen.
Found at: doi:10.1371/journal.pone.0010109.s007 (0.78 MB TIF)
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